Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04290481
Other study ID # B.30.2.ATA.0.01.00/32
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2018
Est. completion date February 1, 2019

Study information

Verified date February 2020
Source Ataturk University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Congenital heart diseases are among the most common congenital anomalies and occur with an incidence of approximately 8ınd12 / 1,000 live births worldwide. This figure does not cover minor lesions such as bicuspid aortic valves and small atrial or ventricular septal defects. Most of these defects do not need treatment or treatment is needed after infancy. Other defects are severe and usually require early treatment in the neonatal period. Critical congenital heart disease is defined as structural heart defects that are associated with hypoxia in the neonatal period and have significant morbidity and mortality potential in early life. Critical congenital heart disease is estimated to be ~3 in 1000 live births. It is estimated that 50% of congenital heart diseases are detected by prenatal ultrasound. Even if a standard neonatal examination is performed, 13 to 55% of patients with critical congenital heart disease can be discharged from the hospital without being diagnosed.

Screening of infants with non-invasive oxygen saturation measurement has been proposed as an adjunct to early detection of critical congenital heart disease.

The American Academy of Pediatrics, the American Cardiology Foundation and the American Heart Association have targeted 7 specific lesions for the pulse oximetry screening protocol: truncus arteriosus, transposition of the great arteries, tricuspid atresia, tetralogy of Fallot, total pulmonary venous return anomaly, hypoplastic left heart syndrome and pulmonary atresia.

The reference values of peripheral perfusion (PPI) index has been established for normal newborns between 1 and 120 h of age.

Lower PPI values than 0.70 may indicate illness. Including cut-off values for PPI in pulse-oximetry screening for duct dependent congenital heart disease is a promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation.

We aimed to investigate screening critical congenital heart disease and also to establish normal values of oxygen saturation and perfusion index at high altitude.


Recruitment information / eligibility

Status Completed
Enrollment 501
Est. completion date February 1, 2019
Est. primary completion date February 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 48 Hours
Eligibility Inclusion Criteria:

- The newborns delivered in Ataturk University Hospital and =34 weeks of gestational age were eligible for the study.

Exclusion Criteria:

- Outborn and premature babies (<34 weeks) were not included. Babies with a prenatal diagnosis of congenital heart disease were excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
oxygen saturation and perfusion index screening
Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.

Locations

Country Name City State
Turkey Ataturk University Medical Faculty Erzurum

Sponsors (1)

Lead Sponsor Collaborator
Ataturk University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establishing threshold values for critical congenital heart disease screening at high altitude We aim to explore whether oxygen saturation and perfusion index threshold values are different compared sea level or not. Postnatal 24-48 hours
Secondary Establishing normal oxygen saturation and perfusion index values at high altitude Postnatal 24-48 hours
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06133530 - Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica N/A
Completed NCT02233582 - Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude Phase 1
Active, not recruiting NCT04604249 - Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World
Not yet recruiting NCT05063643 - Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Recruiting NCT05474287 - SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes N/A
Completed NCT06392373 - High Altitude Muscle Recovery N/A
Completed NCT03851744 - High Altitude and Exogenous Carbohydrate Oxidation N/A
Completed NCT01830530 - HIGH Altitude CArdiovascular REsearch in the ANDES Phase 4
Not yet recruiting NCT06393998 - CO2 Supplement for Treatment of Acute Mountain Sickness N/A
Completed NCT06164665 - Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude Phase 4
Completed NCT04915378 - Hypoxia-altitude Testing to Predict Altitude Related Adverse Health Effects in Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed NCT05798416 - Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude N/A
Not yet recruiting NCT05715476 - The Effect of Different Altitude Levels on Spinal Anesthesia in Cesarean Section Surgery N/A
Recruiting NCT05115721 - Establishing the Reference Interval for Pulse Oxygen Saturation in Neonates at High Altitude
Recruiting NCT06152744 - Evaluation of Membrane Lung Function in High-altitude Regions
Recruiting NCT05304923 - Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude N/A
Recruiting NCT04199650 - Definition of ARDS in Qinghai Province: Verification of Berlin Definition Plateau Criteria